Transforming Cancer Care: OneCell Diagnostics’ Innovation in Recurrence Detection

Rising Cancer Rates and Innovative Solutions

Cancer is a major health threat, with an expected increase in cases to over 35 million by 2050, up 77% from 2022. The World Health Organization reports that cancer survivors globally have reached 53.5 million. However, the recurrence of cancer varies significantly among patients. Currently, there are insufficient solutions to effectively diagnose and manage recurrence.

OneCell Diagnostics: A Breakthrough Approach

OneCell Diagnostics is a startup focused on improving cancer care. It offers a blood-based biopsy test that detects cancer recurrence through circulating tumor cells. This method differs from traditional detection techniques like PET scans and MRIs.

The company uses a proprietary process to capture and isolate these tumor cells from a 10ml blood draw. A trained phlebotomist collects the blood samples at the patient’s home. The samples are sent to OneCell’s lab for analysis using advanced scientific methods combined with artificial intelligence. This process, called True-Single-Cell-Multi-omics, provides more detailed insights than typical liquid biopsy tests.

Advanced Technology for Better Diagnosis

OneCell’s biopsy test aims to give oncologists 100 times more information compared to standard tests that focus only on cell-free DNA. The startup also offers an app called iCare. This tool helps oncologists analyze test results using AI, improving their ability to deliver precision oncology care.

The company has developed a special glass bead to help filter cancer cells from blood samples. Their tests cover a range of solid tumors such as breast, lung, and colon cancers. OneCell chooses not to work with new cancer patients due to regulatory issues in the U.S.

Launching in the U.S. Market

OneCell plans to enter the U.S. market after achieving success in India. The company has already assisted nearly 10,000 patients in India and aims to replicate this success in the U.S. market, focusing on patients with recurring cancer.

OneCell competes with companies like Guardant Health and Natera but distinguishes itself through accuracy and lower costs, charging about one-fifth of competitors’ prices. Founded in 2021, OneCell operates in a B2B2C model, providing services through oncologists and hospitals.

Future Growth and Funding

With a staff of 120 in India and 24 in the U.S., OneCell has built partnerships with major hospitals and academic institutions. The company recently raised $16 million in funding to facilitate growth. Their goal is to reach over 1,000 oncologists and one million patients soon.

In summary, OneCell Diagnostics represents an innovative step forward in oncology, aiming to improve cancer recurrence management significantly through advanced technology and patient-centered services.